Global Glioblastoma Multiforme Treatment Market Overview:
According to SPER Market Research, the Global Glioblastoma Multiforme Treatment Market is estimated to reach USD 6.05 billion by 2032 with a CAGR of 9.04%.
Glioblastoma multiforme (GBM) is an astrocytic-differentiated malignant tumour classified by the WHO as grade IV. The description and development of theories about these tumours have been covered in a wide range of historical records since they are among the most frequently clinically diagnosed central nervous system (CNS) oncological entry.The market is anticipated to grow as a result of a number of factors, including increased R&D, favourable regulatory settings, and the rising occurrence of glioblastoma multiforme. A strong pipeline is likely to significantly influence the glioblastoma multiforme (GBM) therapeutic market during the projected timeframe. It is estimated that the occurrence of brain tumours will drive market expansion throughout the course of the anticipated timeframe.The market is predicted to be boosted in the coming years by the growing acceptance of novel medicines and combination therapies. The need for a personalised treatment strategy to handle glioblastoma multiforme is anticipated to rise as a result of tumour heterogeneity and variance in patient-to-patient treatment approaches. The approval of new therapies is anticipated to lengthen the life expectancy of glioblastoma multiforme patients.
Impact of COVID-19 on the Global Glioblastoma Multiforme Treatment Market
The market for glioblastoma treatments has suffered as a result of COVID-19. During the COVID-19 pandemic, many ICU resources, including ventilators, personal protective equipment, and medical personnel, were diverted to COVID-19 cases, leading to the cessation of surgical neuro-oncology treatments. During the pandemic, there was instability in the ability to provide essential cancer patients with effective medical care. Additionally, it appears that individuals with glioblastoma are more susceptible to the COVID-19 infection, which led to the cancellation of surgeries and therapies. The worldwide glioma treatment market consequently has a significant impact on the market.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Drug Class, By Treatment, By End Use |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Amgen, Inc., Amneal Pharmaceuticals, Arbor Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd
|
Global Glioblastoma Multiforme Treatment Market Segmentation:
By Drug Class: Based on the Drug Class, Global Glioblastoma Multiforme Treatment Market is segmented as; Bevacizumab, Carmustine Wafers, Lomustine, Temozolomide, Others.
By Treatment: Based on the Treatment, Global Glioblastoma Multiforme Treatment Market is segmented as; Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy, Tumor Treating Field (TTF) Therapy.
By End Use: Based on the End Use, Global Glioblastoma Multiforme Treatment Market is segmented as; Ambulatory Surgical Centres, Clinics, Hospitals.
By Region: North America accounted for the largest percentage in recent years. Government support for the expansion of the healthcare sector, together with increased awareness of unusual ailments, simple access to top-notch medical facilities, and kind reimbursement policies, are some of the key factors driving regional market growth. Asia Pacific is anticipated to grow at the fastest rate throughout the projection period due to a number of factors, including the introduction of temozolomide generics, an improved economy, an increase in the world's elderly population, and rising healthcare investment.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Glioblastoma Multiforme Treatment Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Glioblastoma Multiforme Treatment Market, By Drug Class, 2019-2032 (USD Million)
6.1. Bevacizumab
6.2. Carmustine Wafers
6.3. Lomustine
6.4. Temozolomide
6.5. Others
7. Global Glioblastoma Multiforme Treatment Market, By Treatment, 2019-2032 (USD Million)
7.1. Chemotherapy
7.2. Immunotherapy
7.3. Radiation Therapy
7.4. Surgery
7.5. Targeted Therapy
7.6. Tumor Treating Field (TTF) Therapy
8. Global Glioblastoma Multiforme Treatment Market, By End Use, 2019-2032 (USD Million)
8.1. Ambulatory Surgical Centers
8.2. Clinics
8.3. Hospitals
9. Global Glioblastoma Multiforme Treatment Market, By Region, 2019-2032 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. Amgen, Inc.
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Amneal Pharmaceuticals
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Arbor Pharmaceuticals, LLC
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. F. Hoffmann-La Roche
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Karyopharm Therapeutics, Inc.
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Merck & Co., Inc.
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Pfizer Inc.
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.)
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Sun Pharmaceutical Industries Ltd.
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Teva Pharmaceutical Industries Ltd.
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
